A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive DisorderMontgomery S.A. · Huusom A.K.T. · Bothmer J.
aImperial College School of Medicine, London, UK; bH. Lundbeck A/S, Copenhagen, Denmark; cLundbeck GmbH & Co., Hamburg, Germany
This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder. The efficacy of escitalopram (10– 20 mg; n = 148) was similar to venlafaxine XR (75– 150 mg; n = 145), based on mean change from baseline to week 8 in Montgomery and Åsberg Depression Rating Scale total score. In ad hoc analyses, escitalopram-treated patients achieved sustained remission significantly faster than did venlafaxine-treated patients. More venlafaxine-treated patients had nausea, constipation, and increased sweating (p < 0.05). When treatment was completed after 8 weeks, significantly more venlafaxine-treated patients had discontinuation symptoms (p < 0.01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care.
Prof. Stuart A. Montgomery
Imperial College School of Medicine
PO Box 8751, London W13 8WH (UK)
Tel. +44 20 8997 2689, Fax +44 20 8566 7986
Number of Print Pages : 8
Number of Figures : 5, Number of Tables : 3, Number of References : 33
Founded 1975 by J. Mendlewicz (Brussels)
Official Journal of the International Pharmaco-EEG Society (IPEG)
Vol. 50, No. 1, Year 2004 (Cover Date: Released June 2004)
Journal Editor: P. Netter, Giessen; J. Mendlewicz, Brussels; B. Saletu, Vienna
ISSN: 0302–282X (print), 1423–0224 (Online)
For additional information: http://www.karger.com/nps